Similar articles

• Use of monoclonal antibodies to T cells (OKT3) for treatment of acute cellular rejection after renal transplantation.

  Birkeland SA, Svendsen V, Rohr N, Hansen BL, Elbirk A, Foged N, Køhler F. Birkeland SA, et al. Transplant Proc. 1988 Jun;20(3):451-4. Transplant Proc. 1988. PMID: 3289183 No abstract available.
• Antilymphocyte antibodies in the treatment of allograft rejection: targets, mechanisms of action, monitoring, and efficacy.

  Norman DJ. Norman DJ. Semin Nephrol. 1992 Jul;12(4):315-24. Semin Nephrol. 1992. PMID: 1410859 Review. No abstract available.
• Monoclonal antibodies for kidney allograft rejection.

  [No authors listed] [No authors listed] Med Lett Drugs Ther. 1986 Oct 10;28(724):97-8. Med Lett Drugs Ther. 1986. PMID: 3531791 No abstract available.
• Randomized controlled trial of a monoclonal antibody against the interleukin-2 receptor (33B3.1) as compared with rabbit antithymocyte globulin for prophylaxis against rejection of renal allografts.

  Soulillou JP, Cantarovich D, Le Mauff B, Giral M, Robillard N, Hourmant M, Hirn M, Jacques Y. Soulillou JP, et al. N Engl J Med. 1990 Apr 26;322(17):1175-82. doi: 10.1056/NEJM199004263221702. N Engl J Med. 1990. PMID: 2157982 Clinical Trial.
• Effect of anti-lymphocyte antibody induction therapy on renal allograft survival.

  Szczech LA, Feldman HI. Szczech LA, et al. Transplant Proc. 1999 May;31(3B Suppl):9S-11S. doi: 10.1016/s0041-1345(99)00094-9. Transplant Proc. 1999. PMID: 10330960 Review.